Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02110693 · ClinicalTrials.gov registry record · NA
The Tobacco, Alcohol, Prescription Medication and Other Substances Tool
A NA study of Substance Use Disorder, sponsored by Friends Research Institute.
- Completed
- Registry status
- NA
- Development phase
- 2,057
- Enrollment target
- 4
- Study locations
NCT02110693: Completed NA study of Substance Use Disorder, sponsored by Friends Research Institute.
NCT02110693 is a NA study of Substance Use Disorder that has completed, run by Friends Research Institute. The registered enrollment target is 2,057 participants, above the 708-participant average among 18 other Substance Use Disorder trials with a reported enrollment target (191% higher). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02110693, a NA study of Substance Use Disorder, has completed, sponsored by Friends Research Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 2,057 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of the study is to develop and validate a questionnaire to screen and assess adult primary care patients for tobacco, alcohol, prescription drug, and drug use and problems related to their use.
Primary Outcome
The Modified World Mental Health Composite International Diagnostic Interview is a structured interview that assesses whether or not the participant meets DSM-5 Diagnostic Criteria
Conditions Studied
Interventions
- OTHER Interviewer and tablet administration of the TAPS Tool
Study Locations (4)
Maryland
- Chase Brexton Health Services - Baltimore
New York
- Bellevue Hospital - New York
North Carolina
- MURDOCK Study - Kannapolis
Virginia
- Virginia Commonwealth University Health System Ambulatory Care Center - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,057 participants |
| Start Date | 2014-03 |
| Est. Completion | 2015-04 |
| Phase | NA |
What the finished NCT02110693 record still lists
NCT02110693 is an interventional study that assigns participants to a tested intervention. Its 2,057 participants enrollment target places it among the larger protocols in the corpus, above the 708-participant average among 18 other Substance Use Disorder trials with a reported enrollment target (191% higher).
The record links to 1 condition, with Substance Use Disorder appearing as the primary indexed condition, and to 1 intervention - of which Interviewer and tablet administration of the TAPS Tool is the first listed.
NCT02110693 reports a single indexed study location in Maryland, New York, North Carolina.
Frequently Asked Questions
What is clinical trial NCT02110693 about?
NCT02110693 is a clinical study titled "The Tobacco, Alcohol, Prescription Medication and Other Substances Tool". The purpose of the study is to develop and validate a questionnaire to screen and assess adult primary care patients for tobacco, alcohol, prescription drug, and drug use and problems related to their use.
What is the current status of trial NCT02110693?
This trial is currently completed. It is a NA study. The enrollment target is 2,057 participants. The study started on 2014-03. Estimated completion is 2015-04.
What conditions does trial NCT02110693 study?
This clinical trial studies the following conditions: Substance Use Disorder.
What interventions are being tested in trial NCT02110693?
The interventions under investigation include: Interviewer and tablet administration of the TAPS Tool (OTHER).
Who is sponsoring clinical trial NCT02110693?
This trial is sponsored by Friends Research Institute, which has 41 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02110693 being conducted?
This trial has 4 study locations across Maryland, New York, North Carolina, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Substance Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02110693's enrollment target sits among peer trials
2,057 2nd of 18 the highest of 18 other Substance Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Substance Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Smoking Cessation CM for Veterans With or at Risk for Cancer
RECRUITING · NA
-
A Type I Hybrid Effectiveness-Implementation Trial of MIO
RECRUITING · NA
-
OSA PAP Treatment for Veterans With SUD and PTSD on Residential Treatment Unit
RECRUITING · NA
-
Personalized Approach to Healthy Use and Recovery (PATH) Trial
RECRUITING · NA
-
Defining Neurobiological Links Between Substance Use and Mental Illness
RECRUITING · NA
-
Successful Transitions and Reintegration Tools for Veterans (START-VETS)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04871542 · 2,062 participants
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
- NCT06521944 · 2,062 participants
RSV Vaccine Pregnancy Registry
- NCT07168993 · 2,063 participants · NA
Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to <30 mm in Diameter, Determined by LDCT.
- NCT05050084 · 2,050 participants · Phase 3
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia